Zang Xinlong, Zhao Xiuli, Hu Haiyang, Qiao Mingxi, Deng Yihui, Chen Dawei
Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China.
Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China.
Eur J Pharm Biopharm. 2017 Jun;115:243-256. doi: 10.1016/j.ejpb.2017.03.013. Epub 2017 Mar 18.
Although most researches and therapies have been focused on the tumor itself, it is becoming clear that immune cells can not only suppress tumor development but support and maintain their malignant type. Promising recent developments in immunology will provide opportunities for tumor-specific immunotherapy, which can orchestrate the patients immune system to target, fight and eradicate cancer cells without destroying healthy cells. However, antitumor immunity driven by self-immune system alone may be therapeutically insufficient. Developments in nanoparticle based drug delivery system can promote immunotherapy and re-educate immunosuppressive tumor microenvironment (TME), which provide promising strategies for cancer therapy. In this review, we will focus on nanoparticle-based immunotherapeutic approaches against cancer, ranging from nanovaccines, artificial antigen presenting cells (aAPCs) to nanoparticles reversing tumor immunosuppressive microenvironment.
尽管大多数研究和治疗都集中在肿瘤本身,但越来越清楚的是,免疫细胞不仅可以抑制肿瘤发展,还能支持并维持其恶性类型。免疫学领域近期令人瞩目的进展将为肿瘤特异性免疫治疗提供机会,这种治疗方法可以协调患者的免疫系统靶向、对抗并根除癌细胞,而不破坏健康细胞。然而,仅由自身免疫系统驱动的抗肿瘤免疫在治疗上可能并不充分。基于纳米颗粒的药物递送系统的发展可以促进免疫治疗,并重塑免疫抑制性肿瘤微环境(TME),这为癌症治疗提供了有前景的策略。在这篇综述中,我们将聚焦于基于纳米颗粒的抗癌免疫治疗方法,范围涵盖纳米疫苗、人工抗原呈递细胞(aAPC)到逆转肿瘤免疫抑制微环境的纳米颗粒。